News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
AcelRx (ACRX) Presents Results From Phase 3 Study Of ARX-04 Following Ambulatory Abdominal Surgeries At Euroanaesthesia 5/26/2016
GlaxoSmithKline (GSK) Decides Not to Initiate Phase III Study for Ionis Pharma (IONS)'s Amyloid Cardiomyopathy Drug 5/26/2016
Cytori Therapeutics (CYTX) Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial 5/25/2016
Innocoll (INNL)'s Painkiller Passes Final Phase III Tests, Heads for 2017 Launch 5/25/2016
Pfizer (PFE)'s Quest to Become a Cancer Powerhouse 5/25/2016
FDA Grants Fast Track Designation To Novavax (NVAX)’ RSV F Vaccine For Older Adults 5/25/2016
Synergy Pharma Presents New In Vitro Data Showing The pH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin 5/25/2016
Seattle Genetics (SGEN) Initiates Pivotal Phase III Trial Of Vadastuximab Talirine (SGN-CD33A) For Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) 5/25/2016
Synergy Pharma Presents New In Vitro Data Showing The pH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin 5/24/2016
Novartis AG (NVS) Trial Stopped Early on Positive Data, Gets Ready to Take on Pfizer (PFE)'s Ibrance 5/24/2016
Eli Lilly (LLY) Projects 20 New Product Launches in 10 Years with 20 Possible Expansions 5/24/2016
Theratechnologies (TH.TO) Says 82.5% of Patients Achieved Primary Endpoint in Phase III Ibalizumab Trial 5/24/2016
After Initial Miss, GlaxoSmithKline (GSK)'s Pioneering Lung Study Shows Positive Results 5/24/2016
Norgine Release: New Positive Phase III Study For NER1006 - The First 1 Litre PEG-Based Bowel Preparation 5/24/2016
Janssen R&D Release: New Phase 3 Study Findings Show STELARA Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn's Disease 5/24/2016
SELLAS Life Sciences Group Announces Upcoming Presentation Of Phase 2 Clinical Results For WT1 Cancer Vaccine At The 2016 ASCO Annual Meeting 5/24/2016
Celsion (CLSN) Announces Presentation Of OVATION Study Clinical Trial Design At Upcoming ASCO 2016 Meeting 5/24/2016
Eisai Inc. (ESALF.PK) To Present Analyses At 2016 ASCO Annual Meeting From Trials Supporting Recent FDA Approvals For The Company's Oncology Therapies 5/24/2016
Xbiotech To Present Positive Preliminary Survival Data On Xilonix At The 18th European Society Of Medical Oncology’s World Congress On Gastrointestinal Cancer 5/24/2016
Shionogi Release: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation 5/24/2016
Cytel Breaks New Ground In Adaptive Designs With East 6.4 Release 5/24/2016
Alkermes (ALKS) To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting 5/24/2016
Vtesse Advances Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease With Dose Selection For Evaluation In Second And Final Portion Of Trial And Expansion Into Europe 5/23/2016
Mast Therapeutics (MSTX) Release: Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At European Society of Cardiology 3rd World Congress On Acute Heart Failure 5/23/2016
AlloSource Distributes First Bioengineered Blood Vessels For Humacyte Phase III Clinical Trial 5/23/2016
NovoCure Enrolls Last Patient In PANOVA Trial Of Tumor Treating Fields Plus Chemotherapy In Advanced Pancreatic Cancer 5/23/2016
Vital Therapies (VTL) Enrolls First Subject In VTL-308 5/23/2016
Synergy Pharma Presents Additional Phase 3 Plecanatide Data In Chronic Idiopathic Constipation At Digestive Disease Week 5/23/2016
FDA Questions Study Findings, Practicality of Novo Nordisk A/S (NVO)'s Diabetes Drug Ideglira 5/23/2016
13 Massachusetts Cancer Biotechs Looking to Shake Things Up at ASCO in June 5/20/2016
Celator Pharma (CPXX) Announces Upcoming Phase 3 Data Presentations At ASCO And European Hematology Association 5/20/2016
Celator Pharma (CPXX) Jumps on Breakthrough Therapy Win for Lead Cancer Drug 5/19/2016
Novartis Pharmaceutical Corporation (NVS) To Present Pivotal Data In Hematologic And Solid Tumor Cancers At 2016 ASCO Annual Meeting 5/19/2016
BioLife Solutions, Inc. (BLFS.OB) And MNX Global Logistics Partner To Support ImmunoCellular Therapeutics, Ltd (IMUC) With Cold Chain Logistics In ICT-107 Phase 3 Clinical Trial In Glioblastoma 5/19/2016
Janssen R&D To Present Data From Six Compounds Including Daratumumab And Ibrutinib At The 2016 ASCO Annual Meeting 5/19/2016
AbbVie (ABBV) Demonstrates Progress In Oncology Research At ASCO 2016 Annual Meeting With Multiple Abstracts Evaluating Eight Medicines Across Cancer Types 5/19/2016
Amgen (AMGN) Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients 5/19/2016
Phase III Study Of Genentech (RHHBY)’s Alecensa (Alectinib) Showed Superior Efficacy Versus Crizotinib In Japanese People With A Specific Type Of Lung Cancer 5/19/2016
Array BioPharma (ARRY) Announces Key Data From NRAS-Mutant Melanoma And BRAF-Mutant Colorectal Cancer ASCO 2016 Presentations 5/19/2016
Bayer (BAY) To Showcase Latest Oncology Research At ASCO 2016 5/19/2016
Genmab A/S (GEN.CO) Announces Positive Topline Result In Phase III POLLUX Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma 5/19/2016
AbbVie (ABBV)'s Leadership In Gastroenterology Showcased At Digestive Disease Week With New HUMIRA (Adalimumab) Long-Term, Real-World Research And Promising Anti-IL-23 Antibody Late-Breaking Data 5/19/2016
Infinity Pharmaceuticals Inc. (INFI) Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming European Hematology Association And ASCO Meetings 5/19/2016
Bristol-Myers Squibb (BMY) Release: Two-Year Overall Survival Data From Two Pivotal Opdivo (Nivolumab) Trials Demonstrate Sustained Benefit In Patients With Advanced Non-Small Cell Lung Cancer 5/19/2016
Merck & Co. (MRK) Release: New KEYTRUDA (Pembrolizumab) Data From KEYNOTE-006 And KEYNOTE-001 In Advanced Melanoma, Including Updated Survival Data, To Be Presented At 2016 ASCO Annual Meeting 5/19/2016
Celgene (CELG) Announces Presentations Of Investigational Studies In Solid Tumor And Blood Cancers At ASCO 2016 5/19/2016
Provectus Announces Abstract Available Online Of Trials In Progress; Abstract For Poster Presentation At ASCO Annual Meeting 5/19/2016
ImmunoGen (IMGN) Reports Efficacy And Safety Data From A 46-Patient Cohort Of Mirvetuximab Soravtansine In Fra-Positive Ovarian Cancer 5/19/2016
Chugai Pharma To Present Japanese Phase III Results On Alecensa At ASCO 5/19/2016
AstraZeneca PLC (AZN)'s Gastric Cancer Drug Lynparza Flunks Phase III Test 5/18/2016
Catalyst Pharma (CPRX)’s Firdapse Phase III Study Published In Muscle & Nerve 5/18/2016
Breadth And Depth Of Bristol-Myers Squibb (BMY)’s Immuno-Oncology Clinical Development Program To Be Showcased At 2016 ASCO Annual Meeting 5/18/2016
RDD Pharma Announces First Patient Dosed In Phase 3 Clinical Trial For Chronic Anal Fissure 5/18/2016
AstraZeneca PLC (AZN)'s Asthma Drug Hits Phase III Goal, Predicted to Reach Market in 2017 5/18/2016
Asterias Biotherapeutics Reports First Quarter Results 5/17/2016
PBM Capital Acquires Phase III Platelet Drug For Chronic Liver Disease Patients 5/17/2016
Aimmune (AIMT) Announces First Quarter 2016 Financial Results And Provides Corporate Update 5/17/2016
European Scleroderma Trial Investigating Cytori Therapeutics (CYTX) Cell Therapy To Be Presented In Japan 5/17/2016
Sorrento (SRNE) Reports Positive Data from Combined Phase II & III Clinical Study Of STI-004 5/16/2016
Akcea Therapeutics Announces Completion Of Enrollment In Phase 3 COMPASS Trial Of Volanesorsen 5/16/2016
SillaJen Announces Commercial Manufacturing Agreement With ABL Europe For Lead Oncolytic Virus, Pexa-Vec 5/16/2016
Celsion (CLSN) Reports First Quarter 2016 Financial Results And Provides Business Update 5/16/2016
Janssen Biotech Inc. (JNJ) To Present New Inflammatory Bowel Disease Data At Digestive Disease Week Meeting 5/16/2016
Theravance Biopharma (TBPH) Release: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV (Telavancin) As A Treatment For Staphylococcus Aureus HABP/VABP, Including Cases Caused By MRSA 5/16/2016
Boehringer Ingelheim Release: New Presentations At American Thoracic Society 2016 Reinforce OFEV (Nintedanib) Efficacy, Safety And Tolerability Across Range Of Patients With IPF 5/16/2016
TherapeuticsMD, Inc.  (TXMD) Presents Poster At ACOG 2016 With Additional Secondary Endpoint Data From Phase 3 Rejoice Trial 5/16/2016
Pfizer (PFE) Shows Off TRUMENBA Data from Two Large-Scale Phase III Trials 5/13/2016
OncoGenex (OGXI) Reports Financial Results For First Quarter 2016 5/13/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Announces First Quarter 2016 Financial Results 5/13/2016
Hutchison China MediTech (Chi-Med) Completes Enrollment Of 416 Patients In Pivotal Phase III FRESCO Trial With Fruquintinib in Colorectal Cancer 5/13/2016
vTv Therapeutics Reports First Quarter Financial And Operational Results 5/13/2016
Dipexium Pharmaceuticals (DPRX) Announces Completion Of Enrollment Objective In Onestep-2 Pivotal Phase 3 Clinical Trial And First Quarter 2016 Financial Results 5/12/2016
Accera, Inc. Completes Enrollment Of Phase 3 NOURISH AD Study Of AC-1204 For The Treatment Of Alzheimer's Disease 5/12/2016
Soligenix (SNGX) Announces Recent Accomplishments And First Quarter 2016 Financial Results 5/12/2016
Iroko Pharmaceuticals Release: New Data Shows That VIVLODEX Reduces Rescue Medication Use In Patients With Osteoarthritis Pain 5/12/2016
Melinta's Baxdela Successfully Achieves Primary Endpoints in Late Stage Study 5/12/2016
ARCA biopharma Announces First Quarter 2016 Financial Results And Provides Business Update 5/12/2016
Merck & Co. (MRK) To Present Phase III Data On Investigational Medicines Ertugliflozin And MK-1293 At The 76th Scientific Sessions Of The American Diabetes Association 5/12/2016
Theravance Biopharma (TBPH) To Present New Data Analyses From Phase 3 ATTAIN Trials Of VIBATIV (Telavancin) In Treatment Of HABP/VABP At American Thoracic Society 2016 International Conference 5/12/2016
EPIRUS Biopharma to Slash 40% of Workforce, Suspend Lead Clinical Program and Replaces CEO 5/11/2016
Viriom Announces Receipt Of Funding From The Skolkovo Foundation, ChemRar And Torrey Pines Investment To Develop Elpida, A Novel Preventive And Long-Acting Treatment Of HIV/AIDS 5/11/2016
Santen Europe Release: Vekacia (Ciclosporin 1mg/mL Eye Drops) Pivotal Trial Meets Primary And Key Secondary Endpoints 5/11/2016
AVEO Oncology (AVEO) Reports First Quarter 2016 Financial Results And Provides Business Update 5/11/2016
Auris Medical AG (EARS) Provides Business Update And Reports First Quarter 2016 Financial Results 5/11/2016
Puma Biotech (PBYI) Reports First Quarter 2016 Financial Results 5/11/2016
Boehringer Ingelheim Release: Pradaxa: First NOAC To Be Assessed In Prospective Study In Patients With Blood Clots In The Veins Or Venous Sinuses Of The Brain 5/11/2016
Aradigm Corporation (ARDM) Release: Two Presentations On Aradigm’s Inhaled Liposomal Ciprofloxacin Programs At The American Thoracic Society 2016 International Conference 5/11/2016
Ardelyx (ARDX) Reports First Quarter 2016 Financial Results 5/10/2016
NovoCure Reports First Quarter 2016 Financial Results And Provides Company Update 5/10/2016
Ocular Therapeutix (OCUL) Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/10/2016
Tokai Pharmaceuticals (TKAI) Reports First Quarter 2016 Financial Results 5/10/2016
Ariad (ARIA) Reports First Quarter 2016 Financial Results And Progress On Strategic Review 5/10/2016
NewLink Genetics (NLNK) Craters as Pancreatic Cancer Vaccine Fails Phase III Study, May Even Harm Patients 5/10/2016
More Bad News for Chimerix (CMRX) as Brincidofovir Fails Another Late Stage Study 5/9/2016
AbbVie (ABBV) Release: U.S. FDA Expands IMBRUVICA (Ibrutinib) Label To Include Overall Survival Data In Previously Untreated Chronic Lymphocytic Leukemia (CLL) And New Indication For Small Lymphocytic Lymphoma (SLL) Patients 5/9/2016
Janssen Biotech Inc. (JNJ) Release: FDA Expands IMBRUVICA Label To Include New Data From Two Key Phase 3 Trials, Adding Overall Survival And Combination Data 5/9/2016
Allergan (AGN) And Gedeon Richter (RIG2.F) Announce Positive Phase III Results For Ulipristal Acetate 5 And 10 Mg In The Treatment Of Uterine Fibroids 5/9/2016
Celsion (CLSN) To Hold First Quarter 2016 Financial Results Conference Call On Monday, May 16, 2016 5/9/2016
Dimension Therapeutics Announces Preclinical Data From Bayer-Partnered Hemophilia A Program At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting 5/9/2016
Incyte (INCY) Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs 5/9/2016
bluebird bio (BLUE) Presents Oncology And Gene Therapy Data At The ASGCT 19th Annual Meeting 5/9/2016
LUME-Meso Trial Enrolls First Patient: Boehringer Ingelheim’s New Pivotal Study Investigating Nintedanib For The Treatment Of Malignant Pleural Mesothelioma 5/9/2016
Neurocrine Biosciences (NBIX) Reports First Quarter 2016 Results 5/6/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: RGN-259 Confirms Efficacy In Signs And Symptoms Of Dry Eye 5/6/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Receives Regulatory Approval In Canada, The UK And The Netherlands To Initiate ICT-107 Phase 3 Trial In Newly Diagnosed Glioblastoma 5/6/2016
Sophiris Bio (SPHS) To Present Topsalysin Phase 3 Data From Positive PLUS-1 Study As A Late Breaking Poster During The 111th American Urological Association Annual Meeting 5/6/2016
AcelRx (ACRX) Presents Subgroup Analysis Demonstrating Positive Results Of ARX-04 By Type Of Abdominal Surgery 5/6/2016
Neurocrine Biosciences (NBIX) Announces Additional Valbenazine (NBI-98854) Data To Be Presented At The American Psychiatric Association's 2016 Annual Meeting In Atlanta 5/6/2016
SAGE Therapeutics (SAGE) Announces First Quarter 2016 Financial Results 5/6/2016
Akebia (AKBA) Announces First Quarter 2016 Financial Results And Provides Corporate Update 5/6/2016
Horizon Pharma (HZNP) Release: Interferon Gamma-1b) For The Treatment Of People With Friedreich's Ataxia 5/6/2016
Intarcia Touts Large Phase III Trial Diabetes Data, Bags $75 Million 5/6/2016
Bayer (BAY)'s Regorafenib Extends Lives of Liver Cancer Patients in Late Stage Study 5/5/2016
DelMar Pharma Announces $5.6 Million Private Placement Of Preferred Shares 5/5/2016
Infinity Pharmaceuticals Inc. (INFI) Provides Company Update And Reports First Quarter 2016 Financial Results 5/5/2016
Regeneron (REGN) Reports First Quarter 2016 Financial And Operating Results 5/5/2016
Zogenix (ZGNX) Announces New Efficacy And Safety Data On ZX008 For Treatment Of Seizures In Dravet Syndrome 5/5/2016
Aerie (AERI) Completes Enrollment Of Mercury 1 Phase 3 Registration Trial Of Roclatantm (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% 5/5/2016
Cytel Congratulates Flexion (FLXN) On Release Of Phase III Data For Zilretta 5/5/2016
Acceleron Pharma Reports First Quarter 2016 Financial And Operational Results 5/5/2016
Celator Pharma (CPXX) To Report First Quarter 2016 Financial Results On May 10, 2016 5/4/2016
ImmunoCellular Therapeutics, Ltd (IMUC) To Report First Quarter 2016 Financial Results On May 12, 2016 5/4/2016
AcelRx (ACRX) To Present At Two Upcoming Investor Events In May 5/4/2016
Ophthotech Corporation (OPHT) Reports First Quarter 2016 Financial And Operating Results 5/4/2016
GlycoMimetics, Inc. (GLYC) Reports First Quarter 2016 Results 5/4/2016
ProMetic Life Sci (PFSCF.PK) Announces Successful Treatment Of A Plasminogen-Deficient Patient Under An Expanded Access (Compassionate Use) Protocol In The USA 5/4/2016
ProMetic Life Sci (PFSCF.PK) Announces Successful Treatment Of A Plasminogen-Deficient Patient Under An Expanded Access (Compassionate Use) Protocol In The USA 5/3/2016
Tocagen Inc. Presents Intravenous Toca 511 Clinical Data At The 84th AANS Annual Scientific Meeting 5/3/2016
Leading U.S. Cancer Centers Join Delcath Systems (DCTH)'s Focus Phase 3 Trial For Patients With Hepatic Dominant Ocular Melanoma 5/3/2016
Intec Pharma Ltd. Appoints VP Of Clinical And Regulatory Affairs 5/3/2016
Axsome Receives FDA Fast Track Designation For AXS-02 For The Treatment Of The Pain Of Knee Osteoarthritis Associated With Bone Marrow Lesions 5/3/2016
Lexicon Pharma (LXRX) Provides Clinical Pipeline Update And Reports 2016 First Quarter Financial Results 5/3/2016
Array BioPharma (ARRY) Reports Financial Results For The Third Quarter Of Fiscal 2016 5/3/2016
Adocia And Eli Lilly (LLY) Announce Positive Topline Results From A Phase 1b Study Of Repeated Administration Of Ultra-Rapid Biochaperone Lispro U100 In People With Type 2 Diabetes 5/2/2016
Can-Fite BioPharma (CFBI) To Present Data On Cf602 In The Treatment Of Erectile Dysfunction At American Urological Association's Annual Meeting 5/2/2016
CEL-SCI (CVM) Reports Record Monthly Patient Enrollment In April For Its Phase III Head And Neck Cancer Trial 5/2/2016
Elekta Release: New Data Presented At ESTRO 35 Show Positive Cosmesis And Favorable Late Side Effects After Accelerated Partial Breast Irradiation (APBI) With Multicatheter Interstitial Brachytherapy 5/2/2016
OncoGenex (OGXI) To Report First Quarter 2016 Financial Results On May 12, 2016 4/29/2016
Can-Fite BioPharma (CFBI) To Present At Joseph Gunnar & Co.'s Pioneers 2016 Conference In New York City On May 5, 2016 4/29/2016
Eleven Biotherapeutics (EBIO) To Present Data At The Association for Research in Vision & Ophthalmology 2016 Annual Meeting 4/29/2016
Takeda (TKPYY) Release: Phase 3 Trial Results For First Oral Proteasome Inhibitor NINLARO (Ixazomib) Published In The New England Journal Of Medicine 4/28/2016
Celgene (CELG) Reports First Quarter 2016 Operating And Financial Results 4/28/2016
Novartis AG (NVS) Granted Three Breakthrough Badges for Ilaris 4/27/2016
Oasmia Touts Positive Paclical/Apealea Phase III Data; NDA Being Readied for U.S. 4/27/2016
Cytori Therapeutics (CYTX) Announces Timing For Full Enrollment In U.S. Phase III Scleroderma Trial 4/27/2016
Servier Release: Patients With Advanced Metastatic Colorectal Cancer In Europe Now Have A New Treatment Option As LONSURF(Trifluridine/Tipiracil) Receives EU Approval 4/27/2016
Sunovion Pharmaceuticals Inc. Announces Positive Results From Two Phase III Clinical Studies Evaluating SUN-101/Eflow (Glycopyrrolate) In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 4/27/2016
From 20 to 84 Employees in Just Four Years, Booming Blueprint Medicines (BPMC) Maps Out a Plan 4/26/2016
DalCor Randomizes First Patient In The DalGenE Phase 3 Cardiovascular Outcomes Trial 4/26/2016
Celsion (CLSN) Announces Enrollment Of First Patient In The OPTIMA Study In China 4/26/2016
Pfizer (PFE) Release: Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled 4/26/2016
Actinium Pharmaceuticals, Inc. (ATNM.OB) To Host Webinar To Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study For Iomab-B 4/26/2016
JAMA Publishes Phase III Data From Allergic Asthma Trial With ALK-Abello A/S's House Dust Mite SLIT-Tablet, ACARIZAX 4/26/2016
SIGA (SIGA) Announces Enrollment Of First Patients In The Final Cohort Of Phase III Study Of Tecovirimat 4/26/2016
Bristol-Myers Squibb (BMY)’s Opdivo Tagged a Breakthrough by the FDA for Head and Neck Cancer 4/25/2016
No Suicide Risk Linked to Pfizer (PFE)'s Chantix 4/25/2016
PHARNEXT Announces The Opening Of The First U.S. Study Site For Its PLEO-CMT International Pivotal Phase 3 Trial In Charcot-Marie-Tooth Disease Type 1A 4/25/2016
Merck KGaA (MKGAF.PK) Release: Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone 4/25/2016
Biogen (BIIB) R&D Spending Dropped 19% from Last Quarter 4/22/2016
QLT (QLTI) Completes Enrollment In Its Natural History Study 4/22/2016
Celator Pharma (CPXX) To Present Phase 3 Data At 2016 ASCO Annual Meeting 4/21/2016
MedDay Reports Full Data From Pivotal Phase IIb/III MS-SPI / MS-ON Studies With MD1003 In Multiple Sclerosis At AAN 4/21/2016
Novartis AG (NVS)'s Afinitor Significantly Reduces Seizures in TSC Patients in Late Stage Study 4/21/2016
FDA Removes Clinical Hold on Cara Therapeutics (CARA)'s Phase III Postoperative Pain Study 4/20/2016
Basilea (BSLN.SW) Wins $100 Million Contract to Fund Phase III Ceftobiprole Program 4/20/2016
Mitsubishi Tanabe Presents Edaravone Clinical Trial Data In ALS At 2016 American Academy of Neurology Annual Meeting 4/20/2016
Amgen (AMGN) Release: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia 4/20/2016
CytRx (CYTR) To Present Updated Aldoxorubicin Clinical Trial Data At The ASCO Annual Meeting In June 2016 4/20/2016
Exelixis (EXEL)-Discovered Compounds To Be Featured In 18 Presentations At 2016 ASCO Annual Meeting 4/20/2016
Genmab A/S (GEN.CO) Announces Daratumumab Data To Be Presented At 2016 ASCO Annual Meeting 4/20/2016
AbbVie (ABBV) Release: Data Presented At AAN Highlight Impact Of ZINBRYTA (Daclizumab HYP) On Cognitive Outcomes And The Reversibility Of Its Targeted Mechanism Of Action 4/20/2016
Eli Lilly (LLY) Abandons Development of Transition Therapeutics (TTH.TO)' Diabetes Candidate TT401 4/19/2016
Marathon Pharma Presents Analyses At American Academy of Neurology Of A Phase III Clinical Study Of Deflazacort In Patients With Duchenne Muscular Dystrophy (DMD) 4/19/2016
Northwestern Medicine Release: New Research Finds Islet Transplantation Effective To Treat Type 1 Diabetes Complicated By Severe Hypoglycemia 4/19/2016
Tris Pharma, Inc. Announces The Launch Of DYANAVEL XR (Amphetamine) Extended-Release Oral Suspension, CII For The Treatment Of Children With ADHD 4/19/2016
XBiotech USA (XBIT) To Present Pivotal Phase III Data On Xilonix At European Society Of Medical Oncology’s World Congress On Gastrointestinal Cancer 4/19/2016
Bristol-Myers Squibb (BMY) Release: First Presentation Of Overall Survival Data For Opdivo (Nivolumab) Shows Significant Survival Benefit At One-Year Versus Investigator’s Choice In Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck 4/19/2016
Celator Pharma (CPXX) Reports On Previously Suspended Investigator-Initiated Clinical Study 4/19/2016
Dynavax (DVAX) Presents Pivotal Phase 3 Data Showing HEPLISAV-B Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B 4/19/2016
Pfizer (PFE) Announces Positive Top-Line Results For Phase III PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib) 4/19/2016
Acucela Announces End Of Treatment Period In Phase 2b/3 Clinical Trial Of Emixustat Hydrochloride 4/19/2016
Celsion (CLSN) Presents Compelling Data At AACR 2016 Demonstrating Synergistic Anti-Cancer Effect Of GEN-1 IL-12 Immunotherapy Plus Avastin And Doxil 4/19/2016
Merck & Co. (MRK)'s Hep C Drug ZEPATIER Shows Cure Rates as High as 96% in Phase III Studies 4/18/2016
RedHill Biopharma (RDHL) Announces Positive FDA Meeting On RHB-105 Path To Approval And Planned Confirmatory Phase III Study For H. Pylori Infection 4/18/2016
Celator Pharma (CPXX) Announces New Data For VYXEOS In FLT3-ITD Mutated AML Cells Derived From Patients With Newly Diagnosed AML To Be Presented At The AACR Annual Meeting 4/18/2016
AVANIR (AVNR) To Present Data On NUEDEXTA And ONZETRA Xsail At American Academy of Neurology 2016 Annual Meeting 4/18/2016
Morphotek Announces Publication Of Phase 3 Results From Morab-003-004 Trial In Platinum-Sensitive Ovarian Cancer Patients 4/18/2016
Biogen (BIIB) Release: TECFIDERA Data Confirm Strong And Sustained Efficacy In Newly Diagnosed MS Patients And Real-World Effectiveness 4/18/2016
Teva (TEVA) Presents New Data For SD-809 In Huntington Disease At 68th American Academy of Neurology Annual Meeting In Vancouver, B.C. 4/18/2016
Merck & Co. (MRK) Announces Results From Phase 3 Studies Of ZEPATIER (Elbasvir And Grazoprevir) In Chronic Hepatitis C Patient Populations At The International Liver Congress 4/18/2016
Seattle Genetics (SGEN) Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances At AACR Annual Meeting 4/18/2016
Gilead (GILD) Announces Multiple Scientific Presentations Demonstrating Broad Utility Of Sofosbuvir-Based Hepatitis C Therapies 4/18/2016
Titan Pharma (TTP) Announces Presentation Of Probuphine Phase III Data At American Society Of Addiction Medicine Annual Conference 4/18/2016
AbbVie (ABBV) Announces Real-World Data With VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) And EXVIERA (Dasabuvir Tablets) From Large German Hepatitis C-Registry 4/15/2016
Enanta Pharmaceuticals, Inc. Announces High SVR Rates With AbbVie (ABBV)’s VIEKIRAX + EXVIERA Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients 4/15/2016
Braeburn Pharma Release: Probuphine Phase III Data Presented At American Society Of Addiction Medicine (ASAM) Annual Meeting 4/15/2016
Repros Therapeutics (RPRX) to Ditch Efforts to Seek Approval of Testosterone Drug in the U.S. if Key Study Fails 4/15/2016
Gilead (GILD)'s Hep B Candidate Delivers in Two Late-Stage Studies 4/15/2016
ContraVir Invited To Present CMX157 Data At CHI's Eleventh Annual Drug Discovery Chemistry Conference 4/14/2016
Enanta Pharmaceuticals, Inc. Announces High SVR Rates With AbbVie (ABBV)’s Viekirax + Exviera Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients 4/14/2016



//-->